Board of Directors and CEO

David Westberg


CEO since 2015

Westberg has a MSc degree with many years of experience in the pharmaceutical industry, including Pharmacia, Pharmacia-UpJohn and Orexo. Westberg has had various leading positions including global project leader for product development projects and Director Pharmaceutical development and has been part of the executive team for sterile manufacturing at Pharmacia-UpJohn in Sweden.

Westberg has since he left Pharmacia-UpJohn worked as an independent consultant and has as such held position as overall project leader for drug development projects at Orexo AB (Edluar and Zubsolv) from early development, through formulation development and clinical studies to registration for FDA approval in the US.

In addition, David Westberg has worked as a consultant on business development assignments in the pharmaceutical industry.

No other assignments.

Hans Arwidsson

Chairman of the board

Chairman of the board since 2017, Board member since 2016

Hans Arwidsson has a broad experience from the pharmaceutical industry through leading positions in research, marketing and production at AstraZeneca during the years 1984-2001. He is the CEO of Eurocine Vaccines AB (publ.), has also been CEO of LipoCore Holding (2001-2003) and Biosergen AS (2004-2007) and currently sits on the Board of Directors of XSpray Pharma AB (publ.). Hans Arwidsson is a pharmacist (1984) and a doctor of pharmaceutical science (1991) from Uppsala University and holds an MBA from Stockholm School of Economics (1996).

Bengt Gustavsson

Board member

Board member since 2017

Bengt Gustavsson has many years of experience from the pharmaceutical industry in Sweden and the Nordic countries, and has been, among other things, Nordic Medical Director at Novartis Oncology (2002-2005, 2007-2011), Nordic Clinical Research Director at Sanofi-Aventis (2005-2007) and Nordic Medical Chief at Celgene (2012-2017). Since the fall of 2017, Bengt has been Head of Medical Relations at Oncopeptides AB. Bengt Gustavsson is a former reserve officer in the Air Force, pharmacist (1987) and doctor of medical science (pathology) from Uppsala University (1994). He also holds an EUCOR / ECPM degree in pharmaceutical medicine from the EUCOR universities in Basel, Freiburg and Strasbourg (1999).

Magnus Westgren

Board member

Board member since 2015

Magnus has been Head of Obstetrics at Karolinska University Hospital since 1990 and has been Professor and Head of Department at Karolinska University Hospital since 2006.

1982 MD, Lund University, 1983 DM Sci (Ph.D.), Obstetrics and Gynecology, Lund University. Postdoctoral work 1984-1985 at the Department of Obstetrics and Gynecology at Women’s Hospital University of Southern California. Professor Fetal Medicine Karolinska Institutet, Head of Obstetrics and Gynecology, CLINTEC at Karolinska Institutet, Scientific consultant and advisor to the National Board of Health, Supervisors for 25 doctoral students and has published more than 230 scientific reports

Other ongoing assignments: Board member of MedSciNet AB and M3dtec Innovations AB

Urban Paulsson

Board member

Board member since 2019

Urban Paulsson is a lawyer from Lund University with a degree in 1988. He has worked for more than 25 years in the pharmaceutical industry with various legal issues and in various roles including as General Counsel and Vice Pesident Corporate Development at Camurus AB and General Counsel at Vitrolife AB. In recent years he has been involved in starting four biotech companies, e.g. Coromant sold to Bristor-Myers Squibb. Previously, he worked as a lawyer and partner at the law firms Bird & Bird and Nordia.
Urban is also active as a life science investor.

Otto Skolling

Board member

Board member since 2019

Otto Skolling MSc from KTH. He has worked for more than 25 years in the pharmaceutical industry, primarily in business development and financing, but also in product development. Otto has worked at Pharmacia-UpJohn (Project director), Novozymes (Director Product Pipeline, Business Development & Director M&S Biopharmaceutical ingredients), Karolinska Development (Vice President Business Development / Portfolio Management). Otto also has extensive experience from board work from start-up companies in the pharmaceutical industry.

Anders Johansson

Board member

Board member since 2019

Anders Johansson holds a doctorate in materials chemistry from Uppsala University and is co-founder of Nanexa. He has previous experience of working as a patent consultant at Bjerkéns KB patent office. There is an agreement that Anders and Mårten Rooth, another of Nanexa’s founders, should alternately be part of the board.